QRxPharma Information

QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) is a specialty pharmaceutical company and has been focused on the development and commercialisation of new treatments for pain management and abuse prevention products. The Company’s Dual Opioid® platform technology – a patented fixed-ratio combination of morphine and oxycodone – provides effective analgesia with the potential to decrease clinically important opioid-related side effects, in particular respiratory depression. QRxPharma has four complementary pain management product formulations in late and early stage clinical development including: Moxduo® IR, an immediate release oral capsule for acute pain; an abuse deterrent formulation of Moxduo IR®, Moxduo® CR, a controlled release oral tablet (with abuse deterrent and tamper resistant technologies) for chronic pain; and Moxduo® IV, an intravenous formulation for moderate to severe hospital-based pain. On 14 August 2014 the Company announced that it is halting all further development work on the Moxduo portfolio of products.